Diagnosis of ovarian carcinomas

Details Diagnosis of ovarian carcinomas Diagnosis of ovarian carcinomas

2007-09-18

2007-09-18

Canella, Karen A. (Department: 1643)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving antigen-antibody binding, specific binding protein...

C436S063000, C436S064000, C436S504000

Reexamination Certificate

active

10233150

ABSTRACT:
The invention is directed to compositions and methods for the detection of a malignant condition, and relates to the discovery of soluble and cell surface forms of HE4apolypeptides, including HE4athat is overexpressed in ovarian carcinomas. In particular the invention provides a nucleic acid sequence encoding HE4a, and also provides a method of screening for the presence of a malignant condition in a subject by detecting reactivity of an antibody specific for a HE4apolypeptide with a molecule naturally occurring in soluble and/or cell surface form in a sample from such a subject, and by hybridization screening using an HE4anucleotide sequence, as well as other related advantages.

REFERENCES:
patent: 2002/0182619 (2002-12-01), Lillie et al.
patent: 0 440 321 (1991-08-01), None
patent: 1 033 401 (2000-09-01), None
patent: WO 00/50900 (2000-08-01), None
patent: WO 00/77191 (2000-12-01), None
patent: WO01/16354 (2001-03-01), None
patent: WO 01/16354 (2001-03-01), None
patent: WO 01/59064 (2001-08-01), None
patent: WO 02/00677 (2002-01-01), None
patent: WO 02/071928 (2002-09-01), None
Clark (Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man, 1993, p. 1).
Abstract of Cinader, Medical Clinics of North America, 1972, vol. 56, pp. 801-836.
Hough et al (Cancer Research, 2000, vol. 60, pp. 6281-6287).
Bingle et al, Oncogene, 2002, vol. 21, pp. 2768-2773.
Freshney, The Culture of Animal Cells, 1994, p. 5, under the heading “Major Differences in Vitro” and pp. 349-350.
Scholler et al (PNAS, 1999, vol. 96, pp. 11531-11536).
Paul, Fundamental Immunology, (text), 1993, pp. 1157-1170.
Allum. W. et al., “Monoclonal Antibodies in the Diagnosis and treatment of Malignant Conditions.”Surg. Ann. 18:41-64. 1986.
Bast. R. et al., “A Radioimmunoassay using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian Cancer.”N. Eng. J. Med. 309(15):883-887. Oct. 1983.
Bingle. L. et al., “The Putative Ovarian Tumor Marker Gene HE4 (WFDC2). is Expressed in Normal Tissues and Undergoes Complex Alternative Splicing to Yield Multiple Protein Isoforms.”Oncogene 21:2768-2773. Jan. 2002.
Bell. R. et al., “The Performance of Screening Tests for Ovarian Cancer: Results of a Systematic Review.”Br. J. Obstet. Gynaecol. 105(11):1136-1147. Nov. 1998.
Burdon. T. et al., “Over-Expression of an Endogenous Milk Protein Gene in Transgenic Mice is Associated with Impaired Mammary Alveolar Development and aMilchlosPhenotype.”Mechanisms Dev. 36:67-74. 1991.
Chang. K. et al., “ Molecular Cloning of Mesothelin. a Differentiation Antigen Present on Mesothelium. Mesotheliomas. and Ovarian Cancers.”Proc. Natl. Acad. Sci. USA 93:136-140. Jan. 1996.
Chang. K. et al., “Frequent Expression of the Tumor Antigen CAK1 in Squamous-Cell Carcinomas,”Int. J. Cancer 51:548-554. 1992.
Chang. K. et al., “Isolation and Characterization of a Monoclonal Antibody. K1. Reactive with Ovarian Cancers and Normal Mesothelium,”Int. J. Cancer 50:373-381, 1992.
Chang, K. et al., “Characterization of the Antigen (CAK1) Recognized by Monoclonal Antibody K1 Present on Ovarian Cancers and Normal Mesothelium.”Cancer Research 50(1):181-186. Jan. 1992.
Chowdhury. P. et al., “Isolation of a High-Affinity Stable Single-Chain Fv Specific for Mesothelin from DNA-Immunized Mice by Phage Display and Construction of a Recombinant Immunotoxin with Anti-tumor Activity.”Proc. Natl. Acad. Sci. USA 95:669-674. Jan. 1998.
Cioffi. M. et al., “OVCA (CA125) Second Generation” Technical Aspects and Serum Levels in Controls, Patients with Liver Disease, Pregnant Women and Patients with Ovarian Disease.Tumori 83(2):594-598, Mar.-Apr. 1997.
Dandekar. A. et al., “Complete Sequence Analysis of cDNA Clones Encoding Rat Whey Phosphoprotein: Homology to a Protease Inhibitor,”Proc. Natl. Acad. Sci. USA 79(13):3987-3991. Jul. 1982.
Gebauer. G. et al., “Timor Market Concentrations in Normal and Malignant Tissues of Colorectal Cancer Patients and Their Prognostic Relevance.”Anticanc. Res. 17(4B):2939-2942. Jul.-Aug. 1997.
Grütter, M. et al., “The 2.5 Å X-Ray Crystal Structure of the Acid-Stable Proteinase Inhibitor from Human Mucous Secretions analysed in its Complex with Bovine α-Chymotrypsin.”EMBO 7(2):345-351. Feb. 1988.
Hagiwara. k. et al.. “Mouse SWAM1 and SWAM2 are Antibacterial Proteins Composed of a Single Whey Acidic Protein Motif.”J. Immunol.. 170(4):1973-1979. 2003.
Heinzel. R. et al., “Molecular Cloning and Expression of cDNA for Human Antileukoprotease from Cervix Uterus,”Eur. J. Biochem. 160(1):61-67. Oct. 1986.
Hellström, I. et al.. “Overexpression of HER-2 in Ovarian Carcinomas.”Cancer Res. 61:2420-2423, Mar. 2001.
Hirokawa, S. et al., “Neuroblastoma in an Adult with a High Serum Level of Carbohydrate Antigen, CA125: Report of a Case.”Surg. Today 28:349-354. 1998.
Hough , C. et al., “Large-Scale Serial Analysis of Gene Expression Reveals Genes Differentially Expressed in Ovarian Cancer.”Cancer Res. 60:6281-6287. Nov. 2001.
Ind, T. et al., “Serum Concentrations of Cancer Antigen 125. Placental Alkaline Phosphatase. Cancer-Associated Serum Antigen and Free Beta Human Chorionic Gonadotrophin as Prognostic Marker for Epithelial Ovarian Cancer,”Br. J. Obstet. Gynaecol. 104(9):1024-1029. Sep. 1997.
Kirchhoff. C. et al., “A Major Human Epididymis-Specific cDNA encodes a Protein with Sequence Homology to Extracellular Proteinase Inhibitors.”GenBank Accession # X63187. Dec. 1991.
Kirchhoff. C. et al., “A Major Human Epididymis-Specific cDNA encodes a Protein with Sequence Homology to Extracellular Proteinase Inhibitors.”Biol. Reprod. 45(2):350-357. Aug. 1991.
Kojima. T. et al.. “Molecular Cloning and Expression of Megakaryocyte Potetiating Factor cDNA.”J. Biol. Chem. 270(37):21984-21990. Sep. 1995.
Kudoh. K. et al.. “Preoperative Determination of Several Serum Tumor Markers in Patient with Primary Epithelial Ovarian Carcinoma.”Gynaecol. Obstet. Invest. 47(1):52-57. Jan. 1999.
Larsen. M. et al.. “Molecular Cloning and Expression of ps20 Growth inhibitor.”J. of Biol. Chem. 273(8):4574-4584. Feb. 1998.
Lloyd, K. et al., “ Isolation and Characterization of Ovarian Cancer Antigen CA 125 Using a New Monoclonal Antibody (VK-8): Identification as a Mucin-Type Molecule.”Int. J. Cancer 71:842-850, 1997.
Meier, W. et al., “Significance of Tumor Marker Determinations in the Primary Therapy of Ovarian Cancer,”Anticancer Res. 17(4B):2949-2952. Jul.-Aug. 1997.
Meier, W. et al., “CA125 Based Diagnosis and Therapy in Recurrent Ovarian Cancer.”Anticancer Res. 17(4B):3019-3020, Jul.-Aug. 1997.
Meier. W. et al.. Prognostic Significance of CA125 in Patients with Ovarian Cancer and Secondary Debulking Surgery.Anticancer Res. 17(4B):2945-2948. Jul.-Aug. 1997.
Moore. E. et al., Clinical Utility of CA125 Levels in Predicting Laparoscopically Confirmed Salpingitis in Patients with Clinically Diagnosed Pelvic Inflammatory Disease.Infect. Dis. Obstet. Gynaec. 6:182-185, 1998.
Papsidero, I . . . “Recent Progress in the Immunological Monitoring of Carcinomas Using Monoclonal Antibodies.”Semin. Surg. Oncol. 1(4):171-181. 1985.
Sarandakou. A. et al.. “Tumor-Associated Antigens CEA, CA125. SCC and TPS in Gynaecological Cancer.”Eur. J. Gynaecol. Oncol. 19:73-77. 1998.
Sarandakou, A.. et al., “Vaginal Fluid Serum CEA. CA125 and SCC in Normal Conditions and in Benign and Malignant Diseases of the Genital Tract.”Acta Oncol. 36(7):755-759. 1997.
Schmandt. R. et al.. “Differential Expression of the Secreted Protease Inhibitor. HE4. in Epithelial Ovarian Cancer,”Gynecologic Oncology 80(2):319. Feb. 2001.
Scholler. N. et al.. “Soluble Member(s) of the Mesothelin/Megakaryocyte Potentiating F

Affiliated with

Also associated with

Rating

Diagnosis of ovarian carcinomas does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Diagnosis of ovarian carcinomas, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diagnosis of ovarian carcinomas will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3737390